



October 3, 2008

Robert Levine MD  
ArchieMD  
3600 FAU BLVD Suite 201  
Boca Raton, FL 33431

**Re: Protocol #: ArchieMD: the science of drugs; an educational evaluation**  
**IRB Tracking #: NID1-08-303**

Dear Dr. Levine,

As your IRB of record for the above referenced study, the Copernicus Group IRB board has reviewed your submission information. Enclosed is your approval notice. Be sure to carefully maintain the original documents so that copies may be made when necessary. As Principal Investigator, you agree to uphold your responsibility to protect the rights and welfare of your subject at all times while adhering to all applicable federal regulations governing the conduct of clinical research trials.

Copernicus Group IRB reserves the right to visit your research site at any time with appropriate prior notice.


We are also enclosing a Copernicus Group IRB Investigator Guidebook that details the IRB's expectations, procedures and contact information. Please carefully read this Guidebook and have your study staff do the same. CGIRB forms and additional information regarding the conduct of clinical trials are available on our web site: [www.cgirb.com](http://www.cgirb.com).

If you have any questions regarding the contents of this letter or your working relationship with Copernicus Group IRB, please do not hesitate to call us at 1-888-303-2224 or email us at [irb@cgirb.com](mailto:irb@cgirb.com). To avoid delay in locating your records we ask that you refer to the IRB Tracking number located in the header of this letter.

We look forward to working with you.

Copernicus Group IRB

cc: Jill Graygo, ArchieMD, Inc. (Email)



**IRB APPROVAL DATED:**  
**October 2, 2008**  
**EXPIRATION DATE: October 1, 2009**

**Investigator: Robert Levine MD**  
**Approval Includes:**  
 Protocol  
 Post feedback computer users  
 ArchieMD Pre-test  
 ArchieMD post-test  
 Parent Memo  
 Principal Investigator  
 Waiver of Documentation of Parental Permission and Assent

**Investigator Address: Robert Levine MD**

ArchieMD  
3600 FAU BLVD Suite 201  
Boca Raton, FL 33431

**Sponsor:** National Institute of Drug Abuse

**Protocol Title:** ArchieMD: the science of drugs; an educational evaluation



**Approval is granted subject to the following considerations:**

- Responsibilities of the Principal Investigator as found in the Investigator Guidebook
- Please note that if revisions are required for any approved item (particularly advertisements), they must be approved prior to use.

**IF YOU HAVE ANY QUESTIONS, CALL COPERNICUS GROUP IRB AT 1-888-303-2224**

This signature certifies that the information contained in this IRB Approval Notice is true and correct as verified by the minutes and records of The Copernicus Group, Inc. It also certifies that The Copernicus Group, Inc. is in full compliance with FDA Code of Federal Regulations (21 CFR Parts 50, 56, 312, and 812 and 45 CFR) and ICH Guidelines.

Signature Megan Aiken Date 10/6/08 IRB TRACKING # NID1-08-303  
 Authorized Signature

 	<b>CGIRB Indemnification Agreement</b>	Internal Use  SEP 25 2008
---	--	---------------------------------

**Re: Name of Sponsor/Company:** ArchieMD, Inc.  
**Protocol #:**  
**Study Title:** ArchieMD: Science of Drugs Evaluation

~~ADD 108-303~~  
 N 108-303 *MT*  
 9/25/08

1. ArchieMD, Inc. ("Sponsor/Company") agrees to defend, indemnify, and hold harmless The Copernicus Group Inc., its employees, agents, and independent contract personnel, and its independent review board and board members, (collectively referred to as "Copernicus Group IRB"), in connection with Copernicus Group IRB's independent review board review activities from and against any and all losses, liabilities, claims, expenses, and judgments, including without limitation litigation costs and reasonable attorney's fees, which losses, liabilities, claims, expenses, and/or judgments may be incurred or asserted, directly or indirectly, in relationship to or as arising from the Study(ies) noted below:

(i) for all studies sponsored by Sponsor/Company beginning on or after 9-16-08 (the "Studies");

OR

(ii) for a single protocol and study: Protocol #          Study Title          (the "Study")

2. However, Sponsor/Company will not indemnify Copernicus Group IRB in connection with losses, liabilities, claims, expenses, and/or judgments which are solely the result of Copernicus Group IRB's negligence or willful misconduct in connection with its independent review board activities as determined by a court.

Sponsor/Company: ArchieMD, Inc.

Robert Levine

Signature

Printed Name

President

9/16/08

Title

Date

The Copernicus Group, Inc.

Dawn Pope  
Director, IRB Services & Study Start Up

Signature

Printed Name

9.29.08

Title

Date